TD Cowen initiated coverage on CeriBell with a new price target
$CBLL
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
TD Cowen initiated coverage of CeriBell with a rating of Buy and set a new price target of $31.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2025 | $19.00 | Strong Buy | Raymond James |
| 6/24/2025 | $30.00 | Buy | BTIG Research |
| 4/4/2025 | $32.00 | Buy | Ladenburg Thalmann |
| 11/5/2024 | $32.00 | Buy | BofA Securities |
| 11/5/2024 | $30.00 | Buy | Canaccord Genuity |
| 11/5/2024 | $32.00 | Overweight | JP Morgan |
| 11/5/2024 | $31.00 | Buy | TD Cowen |
| 11/5/2024 | Outperform | William Blair |
144 - Ceribell, Inc. (0001861107) (Subject)
8-K - Ceribell, Inc. (0001861107) (Filer)
144 - Ceribell, Inc. (0001861107) (Subject)
4 - Ceribell, Inc. (0001861107) (Issuer)
4 - Ceribell, Inc. (0001861107) (Issuer)
Raymond James initiated coverage of CeriBell with a rating of Strong Buy and set a new price target of $19.00
BTIG Research initiated coverage of CeriBell with a rating of Buy and set a new price target of $30.00
Ladenburg Thalmann initiated coverage of CeriBell with a rating of Buy and set a new price target of $32.00
4 - Ceribell, Inc. (0001861107) (Issuer)
4 - Ceribell, Inc. (0001861107) (Issuer)
4 - Ceribell, Inc. (0001861107) (Issuer)
Issued on behalf of Aleen Inc. VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Last month marked a major turning point as Google launched Gemini 3[1], proving that new AI models can now outperform humans on critical tasks. At the same time, global regulators accelerated the shift[2] toward strict rules for AI in medical devices, signaling that the technology is finally ready for real-world commercial use. This rapid move from the lab to the mass market creates a massive opportunity for specialized operators including Aleen Inc. (CSE:ALEN), Moderna, Inc. (NASDAQ:MRNA), GE HealthCare (NASDAQ:GEHC), CeriBell, Inc. (NASDAQ:CBLL), and Palantir Te
SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its proprietary delirium monitoring solution,1 the first and only FDA cleared delirium screening and monitoring device. This clearance further establishes the Ceribell System as an AI-powered brain monitoring platform technology, extending the benefits to a larger population of critically ill patients and providing additional information to assist in diagnosing patients
SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation ClarityⓇ algorithm to detect electrographic seizures in newborns pre-term and older. This clearance makes the Ceribell System the first and only AI-powered point-of-care electroencephalography (EEG) technology available to detect electrographic seizures in all ages of patients, from pre-term neonates through adults. Early detection of seizures rep
SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell" or the "Company"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced the appointment of Erica Rogers to its Board of Directors. Ms. Rogers brings over three decades of experience leading high-growth, innovative medical device companies to Ceribell's Board as the Company executes on its mission to expand patient access to timely brain monitoring in the acute care setting. Ms. Rogers is an accomplished healthcare executive with board experience in both the public and private sectors. She most recently
—Ms. Rodenbush to lead hiring and talent development initiatives— —Mr. Price to focus on market development and penetration— SUNNYVALE, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions ("Ceribell"), today announced the appointments of Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing to its leadership team. "Ms. Rodenbush and Mr. Price bring an impressive wealth of experience to Ceribell, and I am confident that their leadership across our People & Culture and Marketing fu
SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 & Recent Highlights Reported total revenue of $22.6 million in the third quarter of 2025, a 31% increase compared to the same period in 2024Achieved gross margin of 88% compared to 87% for the same period in 2024 Ended the quarter with 615 total active accounts Appointed Erica Rogers to the Board of Directors "We are encouraged by our third quarter performance, which re
SUNNYVALE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third quarter of 2025 after the close of trading on Tuesday, November 4, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 4, 2025. Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 93946
SUNNYVALE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 & Recent Highlights Reported total revenue of $21.2 million in the second quarter of 2025, a 38% increase compared to the same period in 2024Achieved gross margin of 88% in the second quarter of 2025Ended the quarter with 584 total active accounts "We are pleased with our second quarter results, which reflect our successful commercial execution as we accelerate adopt
SC 13G - Ceribell, Inc. (0001861107) (Subject)
SC 13D - Ceribell, Inc. (0001861107) (Subject)